The vascular catheter business of Curative is not a part of the current deal.
ResMed CEO Mick Farrell said: "Curative’s strong clinical, innovation and market reputation in China, combined with ResMed’s global leadership in sleep and respiratory medicine, will help many millions of people in China suffering from sleep-disordered breathing and chronic obstructive pulmonary disease."
Established in 2008, Curative designs and develops medical devices for sleep-disordered breathing and chronic obstructive pulmonary disease.
The company has manufacturing base in Suzhou, China as well as offices in Beijing, Germany and the US. It has a distributor network across China and in other select markets.
Once the deal concludes, both firms will retain their operational independence and continue to invest in R&D, manufacturing, marketing and sales teams in China.
Curative will preserve its name, brands, and innovative offerings developed for the Chinese market and other global markets.
Curative employees, including the founder and CEO Jason Sun, will provide services as members of the combined ResMed and Curative team.
Subject to customary closing conditions, the deal is expected to complete by the end of this year.
With operations in around 100 countries, ResMed provides devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases.
Image: ResMed to acquire Curative Medical that provides medical devices for sleep-disordered breathing and chronic obstructive pulmonary disease. Photo: courtesy of stockimages/ FreeDigitalPhotos.net.
